{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:49:26Z","timestamp":1782229766231,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cjca.2025.12.012","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:10:42Z","timestamp":1765843842000},"page":"1247-1257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Extended Treatment with Reduced-Dose Direct Oral Anticoagulants for Venous Thromboembolism: Systematic Review and Bayesian Noninferiority Reanalysis"],"prefix":"10.1016","volume":"42","author":[{"given":"Gabriel Oliveira Teixeira","family":"Lyra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Shih","family":"Katsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela Pimentel","family":"Pincelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitor Paiva de","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Lucas de Lima","family":"Prado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel I. Dos Santos","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Amaral","family":"Tinoco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Ant\u00f4nio Prado","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caio Julio Cesar dos Santos","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"379","key":"10.1016\/j.cjca.2025.12.012_bib1","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(11)61904-1","article-title":"Pulmonary embolism and deep vein thrombosis","volume":"12","author":"Goldhaber","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2025.12.012_bib2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2025.12.012_bib3","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel Report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2025.12.012_bib4","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jacc.2024.07.044","article-title":"International clinical practice guideline recommendations for acute pulmonary embolism: harmony, dissonance, and silence","volume":"84","author":"Zuin","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.12.012_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3324\/haematol.10516","article-title":"The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism: a prospective cohort study in 1,626 patients","volume":"92","author":"Prandoni","year":"2007","journal-title":"Haematologica"},{"issue":"345","key":"10.1016\/j.cjca.2025.12.012_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJM200107193450302","article-title":"Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis","volume":"19","author":"Agnelli","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.012_bib7","first-page":"31","volume":"314","author":"Couturaud","year":"2015"},{"key":"10.1016\/j.cjca.2025.12.012_bib8","article-title":"Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis","volume":"366","author":"Khan","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2025.12.012_bib9","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/archinternmed.2010.367","article-title":"Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review","volume":"170","author":"Iorio","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2025.12.012_bib10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2025.12.012_bib11","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.7326\/M21-1094","article-title":"Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis","volume":"174","author":"Khan","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2025.12.012_bib12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-139-11-200312020-00007","article-title":"Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis","volume":"139","author":"Linkins","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2025.12.012_bib13","doi-asserted-by":"crossref","unstructured":"Alam U, Ali MA, Ansab M, et al. Extended reduced versus full-dose treatment with factor Xa inhibitors in patients with venous thromboembolism: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials [e-pub ahead of print]. Naunyn Schmiedebergs Arch Pharmacol doi: 10.1007\/s00210-025-04388-1.","DOI":"10.1007\/s00210-025-04388-1"},{"key":"10.1016\/j.cjca.2025.12.012_bib14","first-page":"30","article-title":"Bayesian analytical methods in cardiovascular clinical trials: why, when, and how","volume":"41","author":"Heuts","year":"2025","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2025.12.012_bib15","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2025.12.012_bib16","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2025.12.012_bib17","author":"Spiegelhalter"},{"key":"10.1016\/j.cjca.2025.12.012_bib18","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/sim.6381","article-title":"Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis","volume":"34","author":"Turner","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.cjca.2025.12.012_bib19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/heartjnl-2018-313617","article-title":"Extended treatment of venous thromboembolism: a systematic review and network meta-analysis","volume":"105","author":"Wang","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2025.12.012_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-72088-2","article-title":"Assessment of non-inferiority with meta-analysis: example of hypofractionated radiation therapy in breast and prostate cancer","volume":"10","author":"Trone","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cjca.2025.12.012_bib21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jclinepi.2019.03.003","article-title":"Most noninferiority trials were not designed to preserve active comparator treatment effects","volume":"110","author":"Tsui","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cjca.2025.12.012_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.7326\/0003-4819-145-1-200607040-00011","article-title":"Good enough: a primer on the analysis and interpretation of noninferiority trials","volume":"145","author":"Kaul","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2025.12.012_bib23","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMoa1210384","article-title":"Low-dose aspirin for preventing recurrent venous thromboembolism","volume":"367","author":"Brighton","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.012_bib24","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","author":"Becattini","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.012_bib25","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/CIRCULATIONAHA.114.008828","article-title":"Aspirin for the prevention of recurrent venous thromboembolism the INSPIRE collaboration","volume":"130","author":"Simes","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.12.012_bib26","author":"McElreath"},{"key":"10.1016\/j.cjca.2025.12.012_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v093.i06","article-title":"Bayesian random-effects meta-analysis using the bayesmeta R Package","volume":"93","author":"R\u00f6ver","year":"2020","journal-title":"J Stat Softw"},{"key":"10.1016\/j.cjca.2025.12.012_bib28","author":"Welton"},{"key":"10.1016\/j.cjca.2025.12.012_bib29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","article-title":"A re-evaluation of random-effects meta-analysis","volume":"172","author":"Higgins","year":"2009","journal-title":"J R Stat Soc Series A Stat Soc"},{"issue":"368","key":"10.1016\/j.cjca.2025.12.012_bib30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"21","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.012_bib31","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.012_bib32","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jtha.2024.03.011","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients: the EVE trial","volume":"22","author":"McBane","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cjca.2025.12.012_bib33","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0140-6736(24)02842-3","article-title":"Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial","volume":"405","author":"Couturaud","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2025.12.012_bib34","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for cancer-associated venous thromboembolism","volume":"392","author":"Mah\u00e9","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.012_bib35","article-title":"Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects","volume":"363","author":"Kent","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2025.12.012_bib36","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/eurheartj\/ehac776","article-title":"Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score","volume":"44","author":"De Winter","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2025.12.012_bib37","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.3390\/jcm13082394","article-title":"Long-term efficacy and safety of direct oral anticoagulants at reduced doses in the secondary prevention of venous thromboembolism and post-thrombotic syndrome","volume":"13","author":"Costanzo","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.cjca.2025.12.012_bib38","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1056\/NEJMoa2509426","article-title":"Apixaban for extended treatment of provoked venous thromboembolism","volume":"393","author":"Piazza","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.12.012_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102878","article-title":"Evaluation of extended direct oral anticoagulant dosing strategies in patients with and without cancer from a prospective observational registry","volume":"9","author":"Vlazny","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.cjca.2025.12.012_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12959-025-00749-1","article-title":"\u0391 6-month, multicenter, observational study investigating the treatment of venous thromboembolism in Greece (VICTORIA study)","volume":"23","author":"Savvari","year":"2025","journal-title":"Thromb J"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2025.12.012_bib41","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood-2024-197878","article-title":"Treatment versus prophylactic apixaban or rivaroxaban for extended venous thromboembolic disease management","volume":"144","author":"Schaefer","year":"2024","journal-title":"Blood"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X25015727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X25015727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:27:50Z","timestamp":1782228470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X25015727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0828282X25015727"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2025.12.012","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended Treatment with Reduced-Dose Direct Oral Anticoagulants for Venous Thromboembolism: Systematic Review and Bayesian Noninferiority Reanalysis","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2025.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}